Literature DB >> 9989571

Body weight and leptin plasma levels during treatment with antipsychotic drugs.

T Kraus1, M Haack, A Schuld, D Hinze-Selch, M Kühn, M Uhr, T Pollmächer.   

Abstract

OBJECTIVE: Leptin is produced by fat cells and is presumed to signal the size of the adipose tissue to the brain. The authors investigated whether antipsychotic drugs that often induce weight gain affect circulating levels of leptin.
METHOD: Weight, body mass index, and leptin plasma level were measured weekly over 4 weeks in psychiatric inpatients who received clozapine (N = 11), olanzapine (N = 8), haloperidol (N = 13), or no psychopharmacological treatment (N = 12).
RESULTS: In patients receiving clozapine or olanzapine, significant increases in weight, body mass index, and leptin level were found, whereas these measures remained stable in patients who received haloperidol or no pharmacological treatment.
CONCLUSIONS: Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989571     DOI: 10.1176/ajp.156.2.312

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  38 in total

Review 1.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 2.  The interface of psychiatric disorders and diabetes mellitus.

Authors:  M K Popkin; E A Colon
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

3.  A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.

Authors:  Benjamin U Nwosu; Bruce Meltzer; Louise Maranda; Carol Ciccarelli; Daniel Reynolds; Laura Curtis; Jean King; Jean A Frazier; Mary M Lee
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

4.  Serum ghrelin concentrations in patients receiving olanzapine or risperidone.

Authors:  Takashi Togo; Koichi Hasegawa; Satoshi Miura; Hideki Hosojima; Katsuo Kojima; Mika Shoji; Akihiko Kase; Hirotake Uchikado; Eizo Iseki; Kenji Kosaka
Journal:  Psychopharmacology (Berl)       Date:  2003-10-09       Impact factor: 4.530

5.  Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.

Authors:  R Coccurello; A Caprioli; O Ghirardi; R Conti; B Ciani; S Daniele; A Bartolomucci; A Moles
Journal:  Psychopharmacology (Berl)       Date:  2006-05-13       Impact factor: 4.530

6.  A prospective study of serum ghrelin levels in patients treated with clozapine.

Authors:  F M Theisen; S Gebhardt; T Brömel; B Otto; W Heldwein; M Heinzel-Gutenbrunner; J-C Krieg; H Remschmidt; M Tschöp; J Hebebrand
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

7.  Weight gain and new onset diabetes associated with olanzapine and risperidone.

Authors:  Wildon R Farwell; Timothy E Stump; Jane Wang; Eskinder Tafesse; Gilbert L'Italien; William M Tierney
Journal:  J Gen Intern Med       Date:  2004-12       Impact factor: 5.128

Review 8.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 9.  [Diabetes mellitus as a complication of treatment with atypical neuroleptics. Possible pathomechanisms and treatment recommendations].

Authors:  H Jahn; T Schneider
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

Review 10.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Authors:  Hua Jin; Jonathan M Meyer; Sunder Mudaliar; Dilip V Jeste
Journal:  Schizophr Res       Date:  2008-01-18       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.